Design Therapeutics To Present Update On Progress Of DT-168 Program For FECD At Eyecelerator At Park City 2025 On May 2, 2025
Press Release: Design Therapeutics Appoints Veteran Industry Executive Chris Storgard, M.D., as Chief Medical Officer
Bright Peak Therapeutics Appoints John Schmid to Its Board of Directors
Top Premarket Gainers
12 Health Care Stocks Moving In Friday's Pre-Market Session
Design Therapeutics (DSGN) Upgraded to Buy: Here's Why
Wall Street Analysts See a 31.33% Upside in Design Therapeutics (DSGN): Can the Stock Really Move This High?
RBC Capital Maintains Design Therapeutics(DSGN.US) With Hold Rating, Raises Target Price to $5
RBC Raises Price Target on Design Therapeutics to $5 From $4, Keeps Sector Perform, Speculative Risk
Design Therapeutics GAAP EPS of -$0.24
Design Therapeutics | 10-K: FY2024 Annual Report
Design Therapeutics Provides Corporate Highlights, Anticipated Milestones
Express News | Design Therapeutics Expects Cash And Equivalents Of $245.5M As Of December 31, 2024, To Fund Its Planned Operating Expenses Into 2029
Design Therapeutics | 8-K: Design Therapeutics Highlights Progress Across Lead GeneTAC ® Programs and Reports Fourth Quarter and Full Year 2024 Financial Results
Design Therapeutics 4Q Research and Development Expenses $12.2M >DSGN
Express News | Design Therapeutics Q4 Operating Income USD -16.694 Million
Express News | Design Therapeutics Q4 Net Income USD -13.651 Million
Express News | Design Therapeutics Q4 Basic EPS USD -0.24
Press Release: Design Therapeutics Highlights Progress Across Lead GeneTAC(R) Programs and Reports Fourth Quarter and Full Year 2024 Financial Results
Design Therapeutics to Participate in Leerink's Global Healthcare Conference